Physician profile
Bret Haymore
NPI 1376503102
$5,977.91
in general payments reported to CMS, 2019-2025
31 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $564 · 2021: $606 · 2022: $791 · 2023: $1,107 · 2024: $1,011 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,357 · Education: $23.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,356.73 |
| Education | $23.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,001.83 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $910.74 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $803.24 | 2019-2025 | Dupixent |
| Genzyme Corporation | $690.26 | 2019-2025 | |
| Csl Behring | $381.69 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Kaleo, INC. | $256.35 | 2019-2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $227.52 | 2019-2025 | |
| Optinose US, INC. | $227.49 | 2019-2024 | |
| Ars Pharmaceuticals Operations, INC. | $226.38 | 2025 | Neffy |
| Pfizer INC. | $223.84 | 2019-2025 | |
| Alk-Abello, INC | $160.07 | 2019-2024 | Timothy, Standardized, Standardized Mite D. Farinae, Alternaria Tenuis |
| Amgen INC. | $144.50 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $141.69 | 2021-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $134.03 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
| Genentech, INC. | $74.95 | 2019-2024 | Xolair |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $47.26 | 2022 | |
| Grifols USA, LLC | $46.03 | 2023-2025 | Xembify |
| Octapharma USA, INC. | $42.37 | 2020-2025 | Octagam Immune Globulin (Human) |
| Biocryst US Sales Co., LLC | $28.97 | 2022-2023 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $26.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.83 | 2020-2021 | |
| Dermavant Sciences, INC. | $25.39 | 2024 | Vtama |
| Pharming Healthcare, INC. | $24.58 | 2019 | |
| Greer Laboratories, INC. | $21.56 | 2022 | |
| Aimmune Therapeutics, INC. | $19.55 | 2021 | |
| Galderma Laboratories, L.P. | $17.30 | 2025 | Nemluvio |
| Ionis Pharmaceuticals, INC. | $15.98 | 2025 | Dawnzera |
| Nestle Healthcare Nutrition INC. | $15.33 | 2023 | |
| Shire North American Group INC | $11.43 | 2019 | |
| Cycle Pharmaceuticals INC | $4.82 | 2024 | Sajazir |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bret Haymore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.